On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases (19 views visite)
J Clin Med (ISSN: 2077-0383linking), 2020 Mar 15; 9(3): N/D-N/D.
Export to Esporta in BibTeX Export to Esporta in EndNote
Paper type Tipo di articolo: Journal Article
Impact factor: 6.78, 5-year impact factor Impact factor a 5 anni: 0
Url: Not available. Non disponibile.
Keywords Parole chiave: Crohn’s Disease, Il-6, Adalimumab, Cytokines, Scd163, Ulcerative Colitis, Ustekinumab, Vedolizumab, Zonulin
Affiliations Affiliazioni:
*** IBB - CNR ***
Department of Medical Sciences, University of Turin, 1016 Turin, Italy.
Unit of Gastroenterology, Città della Salute e della Scienza di Torino-Molinette Hospital, 10126 Turin, Italy.
Institute of Biostructure and Bioimaging, CNR c/o Molecular Biotechnology Centre, 10126 Turin, Italy.
References Riferimenti:
Not available. Non disponibili.
J Clin Med (ISSN: 2077-0383linking), 2020 Mar 15; 9(3): N/D-N/D.
Export to Esporta in BibTeX Export to Esporta in EndNote
Paper type Tipo di articolo: Journal Article
Impact factor: 6.78, 5-year impact factor Impact factor a 5 anni: 0
Url: Not available. Non disponibile.
Keywords Parole chiave: Crohn’s Disease, Il-6, Adalimumab, Cytokines, Scd163, Ulcerative Colitis, Ustekinumab, Vedolizumab, Zonulin
Affiliations Affiliazioni:
*** IBB - CNR ***
Department of Medical Sciences, University of Turin, 1016 Turin, Italy.
Unit of Gastroenterology, Città della Salute e della Scienza di Torino-Molinette Hospital, 10126 Turin, Italy.
Institute of Biostructure and Bioimaging, CNR c/o Molecular Biotechnology Centre, 10126 Turin, Italy.
References Riferimenti:
Not available. Non disponibili.
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases
In patients with inflammatory bowel diseases (IBD) undergoing biologic therapy, biomarkers of treatment response are still scarce. This study aimed to evaluate whether serum zonulin, a biomarker of intestinal permeability; soluble CD163 (sCD163), a macrophage activation marker; and a panel of serum cytokines could predict the response to biologic treatment in patients with IBD. For this purpose, we prospectively enrolled 101 patients with IBD and 19 patients with irritable bowel syndrome (IBS) as a control group; 60 out of 101 patients underwent treatment with biologics. Zonulin, sCD163, and cytokines were measured at the baseline in all patients and after 10 weeks of treatment in the 60 patients who underwent biologic therapy. We observed that zonulin levels were higher in IBD patients with active disease compared to those in remission (p = 0.035), and that sCD163 values were higher in patients with IBD compared to those with IBS (p = 0.042), but no association with therapy response was observed for either biomarker. Conversely, interleukin (IL)-6, IL-8, IL-10, and tumor necrosis factor-alpha showed a significant reduction from baseline to week 10 of treatment, particularly in responder patients. By multivariate logistic regression analysis corrected for disease (Crohn's disease or ulcerative colitis), type of biologic drug (Infliximab, Adalimumab, Vedolizumab, or Ustekinumab) and disease activity, the reduction in IL-6 values was associated with a clinical response at 12 months of biological therapy (odds ratio (OR) = 4.75, 95% confidence interval (CI) 1.25-18.02, p = 0.022). In conclusion, the measurement of serum IL-6 in biologics-treated IBD patients may allow for the prediction of response to treatment at 12 months of therapy and thus may help with tailoring personalized treatment strategies.
In patients with inflammatory bowel diseases (IBD) undergoing biologic therapy, biomarkers of treatment response are still scarce. This study aimed to evaluate whether serum zonulin, a biomarker of intestinal permeability; soluble CD163 (sCD163), a macrophage activation marker; and a panel of serum cytokines could predict the response to biologic treatment in patients with IBD. For this purpose, we prospectively enrolled 101 patients with IBD and 19 patients with irritable bowel syndrome (IBS) as a control group; 60 out of 101 patients underwent treatment with biologics. Zonulin, sCD163, and cytokines were measured at the baseline in all patients and after 10 weeks of treatment in the 60 patients who underwent biologic therapy. We observed that zonulin levels were higher in IBD patients with active disease compared to those in remission (p = 0.035), and that sCD163 values were higher in patients with IBD compared to those with IBS (p = 0.042), but no association with therapy response was observed for either biomarker. Conversely, interleukin (IL)-6, IL-8, IL-10, and tumor necrosis factor-alpha showed a significant reduction from baseline to week 10 of treatment, particularly in responder patients. By multivariate logistic regression analysis corrected for disease (Crohn's disease or ulcerative colitis), type of biologic drug (Infliximab, Adalimumab, Vedolizumab, or Ustekinumab) and disease activity, the reduction in IL-6 values was associated with a clinical response at 12 months of biological therapy (odds ratio (OR) = 4.75, 95% confidence interval (CI) 1.25-18.02, p = 0.022). In conclusion, the measurement of serum IL-6 in biologics-treated IBD patients may allow for the prediction of response to treatment at 12 months of therapy and thus may help with tailoring personalized treatment strategies.
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases
No results. Nessun risultato. |
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases
Caviglia GP, Tucci A, Pellicano R, Fagoonee S, Rosso C, Abate ML, Olivero A, Armandi A, Vanni E, Saracco GM, Bugianesi E, Astegiano M, Ribaldone DG
* Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report (13 visite)
J Clin Med (ISSN: 2077-0383linking), 2020 Jul 23; 9(8): N/D-N/D.
Impact Factor: 6.78
Dettagli Esporta in BibTeX Esporta in EndNote
Carli E, Caviglia GP, Pellicano R, Fagoonee S, Rizza S, Astegiano M, Saracco GM, Ribaldone DG
* Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis (16 visite)
Medicina (ISSN: 1010-660xlinking), 2020 Jun 11; 56(6): N/D-N/D.
Impact Factor: 1.205
Dettagli Esporta in BibTeX Esporta in EndNote
Bertani L, Caviglia GP, Antonioli L, Pellicano R, Fagoonee S, Astegiano M, Saracco GM, Bugianesi E, Blandizzi C, Costa F, Ribaldone DG
* Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases (65 visite)
J Clin Med (ISSN: 2077-0383electronic, 2077-0383linking), 2020 May 2; 9(5): N/D-N/D.
Impact Factor: 6.78
Dettagli Esporta in BibTeX Esporta in EndNote
Actis GC, Pellicano R, Fagoonee S, Ribaldone DG
* History of Inflammatory Bowel Diseases (52 visite)
J Clin Med (ISSN: 2077-0383linking), 2019 Nov 14; 8(11): N/D-N/D.
Impact Factor: 5.688
Dettagli Esporta in BibTeX Esporta in EndNote
Squeglia F, Moreira M, Ruggiero A, Berisio R
* The Cell Wall Hydrolytic NlpC/P60 Endopeptidases in Mycobacterial Cytokinesis: A Structural Perspective (163 visite)
Cells (ISSN: 2073-4409linking), 2019 Jun 18; 8(6): N/D-N/D.
Impact Factor: 5.7
Dettagli Esporta in BibTeX Esporta in EndNote
Parisi V, Petraglia L, D'Esposito V, Cabaro S, Rengo G, Caruso A, Grimaldi MG, Baldascino F, De Bellis A, Vitale D, Formisano R, Ferro A, Paolillo S, Davin L, Lancellotti P, Formisano P, Perrone Filardi P, Ferrara N, Leosco D
* Statin therapy modulates thickness and inflammatory profile of human epicardial adipose tissue (177 visite)
Int J Cardiol (ISSN: 0167-5273, 1874-1754electronic, 0167-5273linking), 2019 Jan 1; 274: 326-330.
Impact Factor: 3.121
Dettagli Esporta in BibTeX Esporta in EndNote
Ribaldone DG, Dileo I, Pellicano R, Resegotti A, Fagoonee S, Vernero M, Saracco G, Astegiano M
* Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy (185 visite)
Irish J Med Sci (ISSN: 0021-1265), 2017 Jul 29; 187(2): 385-392.
Impact Factor: 1.045
Dettagli Esporta in BibTeX Esporta in EndNote
Dennehy R, RomanoM, Ruggiero A, Mohamed YF, Dignam SL, Mujica Troncoso C, Callaghan M, Valvano MA, Berisio R, Mcclean S
* The Burkholderia cenocepacia peptidoglycan-associated lipoprotein is involved in epithelial cell attachment and elicitation of inflammation (234 visite)
Cell Microbiol (ISSN: 1462-5814), 2017 May; 19(5): e12691-e12691.
Impact Factor: 4.41
Dettagli Esporta in BibTeX Esporta in EndNote
Miceli M, Dell'Aversana C, Russo R, Rega C, Cupelli L, Ruvo M, Altucci L, Chambery A
* Secretome profiling of cytokines and growth factors reveals that neuro-glial differentiation is associated with the down-regulation of Chemokine Ligand 2 (MCP-1/CCL2) in amniotic fluid derived-mesenchymal progenitor cells (332 visite)
Proteomics (ISSN: 1615-9853), 2016; 16(4): 674-688.
Impact Factor: 4.041
Dettagli Esporta in BibTeX Esporta in EndNote
Accardo A, Vitiello M, Tesauro D, Galdiero M, Finamore E, Martora F, Mansi R, Ringhieri P, Morelli G
* Self-assembled or mixed peptide amphiphile micelles from herpes simplex virus glycoproteins as potential immunomodulatory treatment (418 visite)
Int J Nanomed (ISSN: 1178-2013, 1176-9114, 1176-9114linking), 2014 May 7; 9(1): 2137-2148.
Impact Factor: 4.383
Dettagli Esporta in BibTeX Esporta in EndNote
Castiglione F, Mainenti PP, De Palma GD, Testa A, Bucci L, Pesce G, Camera L, Diaferia M, Rea M, Caporaso N, Salvatore M, Rispo A
* Noninvasive diagnosis of small bowel crohn's disease: Direct comparison of bowel sonography and magnetic resonance enterography (377 visite)
Inflamm Bowel Dis (ISSN: 1078-0998, 1536-4844electronic, 1078-0998linking), 2013 Apr; 19(4): 991-998.
Impact Factor: 5.475
Dettagli Esporta in BibTeX Esporta in EndNote
Ruggiero A, Marchant J, Squeglia F, Makarov V, De Simone A, Berisio R
* Molecular determinants of inactivation of the resuscitation promoting factor B from Mycobacterium tuberculosis (319 visite)
J Biomol Struct Dyn (ISSN: 0739-1102, 1538-0254electronic, 0739-1102linking), 2013 Feb 1; 31(2): 195-205.
Impact Factor: 2.983
Dettagli Esporta in BibTeX Esporta in EndNote
Dolga AM, Letsche T, Gold M, Doti N, Bacher M, Chiamvimonvat N, Dodel R, Culmsee C
* Activation of KCNN3/SK3/K(Ca)2. 3 channels attenuates enhanced calcium influx and inflammatory cytokine production in activated microglia (441 visite)
Glia (ISSN: 1098-1136), 2012 Dec; 60(12): 2050-2064.
Impact Factor: 5.466
Dettagli Esporta in BibTeX Esporta in EndNote
Peluso R, Di Minno MND, Bruner V, Soscia E, Castiglione F, Manguso F, Iervolino S, Scarpa R
* Discovertebral Erosions in Patients with Enteropathic Spondyloarthritis (243 visite)
Journal Of Rheumatology (ISSN: 0315-162x), 2012 Dec; 39(12): 2332-2340.
Impact Factor: 3.258
Dettagli Esporta in BibTeX Esporta in EndNote
Kaprelyants AS, Mukamolova GV, Ruggiero A, Makarov VA, Demina GR, Shleeva MO, Potapov VD, Shramko PA
* Resuscitation-promoting Factors (Rpf): In Search of Inhibitors (331 visite)
Protein Pept Lett (ISSN: 0929-8665, 1875-5305), 2012 Oct; 19(10): 1026-1034.
Impact Factor: 1.994
Dettagli Esporta in BibTeX Esporta in EndNote
Ruggiero A, Tizzano B, Pedone E, Pedone C, Wilmanns M, Berisio R
* Crystal Structure of the Resuscitation-Promoting Factor (Delta DUF)RpfB from M. tuberculosis (333 visite)
J Mol Biol (ISSN: 0022-2836, 1089-8638, 1089-8638electronic), 2009 Jan 9; 385(1): 153-162.
Impact Factor: 3.871
Dettagli Esporta in BibTeX Esporta in EndNote
Selvaggi F, Cuocolo A, Giuliani A, Sciaudone G, Riegler G, Mainolfi C, Caprio MG, Panico M, Fiume I
* The role of scintigraphic defecography in the assessment of bowel function after restorative proctocolectomy for ulcerative colitis (242 visite)
International Journal Of Colorectal Disease (ISSN: 0179-1958, 0179-1958linking), 2006 Jul; 21(5): 448-452.
Impact Factor: 2.006
Dettagli Esporta in BibTeX Esporta in EndNote
Galdiero S, Vitiello M, Amodeo P, D'Isanto M, Cantisani M, Pedone C, Galdiero M
* Structural requirements for proinflammatory activity of porin P2 loop 7 from Haemophilus influenzae (427 visite)
Biochemistry (ISSN: 0006-2960, 1520-4995, 1520-4995electronic), 2006 Apr 11; 45(14): 4491-4501.
Impact Factor: 3.633
Dettagli Esporta in BibTeX Esporta in EndNote
Selavaggi F, Cuocolo A, Giuliani A, Sciaudone G, Riegler G, Mainolfi C, Caprio MG, Panico M, Fiume I
* The Role Of Scientigraphic Defecography In The Assessment Of Bowel Function After Restorative Proctocolectomy For Ulcerative Colitis (195 visite)
Int J Colorectal Dis, 2006; 5: 448-452.
Impact Factor: 2.017
Dettagli Esporta in BibTeX Esporta in EndNote
Fonti R, Latella G, Caprilli R, Frieri G, Marcheggiano A, Sambuy Y
Carbonic anhydrase I reduction in colonic mucosa of patients with active ulcerative colitis (224 visite)
Digestive Diseases And Sciences (ISSN: 0163-2116), 1998; 43(9): 2086-2092.
Impact Factor: 1.972
Dettagli Esporta in BibTeX Esporta in EndNote
Vai a fine pagina Versione per copia e incolla facile Esporta tutto in BibTeX Esporta tutto in EndNote
Caviglia GP, Tucci A, Pellicano R, Fagoonee S, Rosso C, Abate ML, Olivero A, Armandi A, Vanni E, Saracco GM, Bugianesi E, Astegiano M, Ribaldone DG
* Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report (13 visite)
J Clin Med (ISSN: 2077-0383linking), 2020 Jul 23; 9(8): N/D-N/D.
Impact Factor: 6.78
Dettagli Esporta in BibTeX Esporta in EndNote
Carli E, Caviglia GP, Pellicano R, Fagoonee S, Rizza S, Astegiano M, Saracco GM, Ribaldone DG
* Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis (16 visite)
Medicina (ISSN: 1010-660xlinking), 2020 Jun 11; 56(6): N/D-N/D.
Impact Factor: 1.205
Dettagli Esporta in BibTeX Esporta in EndNote
Bertani L, Caviglia GP, Antonioli L, Pellicano R, Fagoonee S, Astegiano M, Saracco GM, Bugianesi E, Blandizzi C, Costa F, Ribaldone DG
* Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases (65 visite)
J Clin Med (ISSN: 2077-0383electronic, 2077-0383linking), 2020 May 2; 9(5): N/D-N/D.
Impact Factor: 6.78
Dettagli Esporta in BibTeX Esporta in EndNote
Actis GC, Pellicano R, Fagoonee S, Ribaldone DG
* History of Inflammatory Bowel Diseases (52 visite)
J Clin Med (ISSN: 2077-0383linking), 2019 Nov 14; 8(11): N/D-N/D.
Impact Factor: 5.688
Dettagli Esporta in BibTeX Esporta in EndNote
Squeglia F, Moreira M, Ruggiero A, Berisio R
* The Cell Wall Hydrolytic NlpC/P60 Endopeptidases in Mycobacterial Cytokinesis: A Structural Perspective (163 visite)
Cells (ISSN: 2073-4409linking), 2019 Jun 18; 8(6): N/D-N/D.
Impact Factor: 5.7
Dettagli Esporta in BibTeX Esporta in EndNote
Parisi V, Petraglia L, D'Esposito V, Cabaro S, Rengo G, Caruso A, Grimaldi MG, Baldascino F, De Bellis A, Vitale D, Formisano R, Ferro A, Paolillo S, Davin L, Lancellotti P, Formisano P, Perrone Filardi P, Ferrara N, Leosco D
* Statin therapy modulates thickness and inflammatory profile of human epicardial adipose tissue (177 visite)
Int J Cardiol (ISSN: 0167-5273, 1874-1754electronic, 0167-5273linking), 2019 Jan 1; 274: 326-330.
Impact Factor: 3.121
Dettagli Esporta in BibTeX Esporta in EndNote
Ribaldone DG, Dileo I, Pellicano R, Resegotti A, Fagoonee S, Vernero M, Saracco G, Astegiano M
* Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy (185 visite)
Irish J Med Sci (ISSN: 0021-1265), 2017 Jul 29; 187(2): 385-392.
Impact Factor: 1.045
Dettagli Esporta in BibTeX Esporta in EndNote
Dennehy R, RomanoM, Ruggiero A, Mohamed YF, Dignam SL, Mujica Troncoso C, Callaghan M, Valvano MA, Berisio R, Mcclean S
* The Burkholderia cenocepacia peptidoglycan-associated lipoprotein is involved in epithelial cell attachment and elicitation of inflammation (234 visite)
Cell Microbiol (ISSN: 1462-5814), 2017 May; 19(5): e12691-e12691.
Impact Factor: 4.41
Dettagli Esporta in BibTeX Esporta in EndNote
Miceli M, Dell'Aversana C, Russo R, Rega C, Cupelli L, Ruvo M, Altucci L, Chambery A
* Secretome profiling of cytokines and growth factors reveals that neuro-glial differentiation is associated with the down-regulation of Chemokine Ligand 2 (MCP-1/CCL2) in amniotic fluid derived-mesenchymal progenitor cells (332 visite)
Proteomics (ISSN: 1615-9853), 2016; 16(4): 674-688.
Impact Factor: 4.041
Dettagli Esporta in BibTeX Esporta in EndNote
Accardo A, Vitiello M, Tesauro D, Galdiero M, Finamore E, Martora F, Mansi R, Ringhieri P, Morelli G
* Self-assembled or mixed peptide amphiphile micelles from herpes simplex virus glycoproteins as potential immunomodulatory treatment (418 visite)
Int J Nanomed (ISSN: 1178-2013, 1176-9114, 1176-9114linking), 2014 May 7; 9(1): 2137-2148.
Impact Factor: 4.383
Dettagli Esporta in BibTeX Esporta in EndNote
Castiglione F, Mainenti PP, De Palma GD, Testa A, Bucci L, Pesce G, Camera L, Diaferia M, Rea M, Caporaso N, Salvatore M, Rispo A
* Noninvasive diagnosis of small bowel crohn's disease: Direct comparison of bowel sonography and magnetic resonance enterography (377 visite)
Inflamm Bowel Dis (ISSN: 1078-0998, 1536-4844electronic, 1078-0998linking), 2013 Apr; 19(4): 991-998.
Impact Factor: 5.475
Dettagli Esporta in BibTeX Esporta in EndNote
Ruggiero A, Marchant J, Squeglia F, Makarov V, De Simone A, Berisio R
* Molecular determinants of inactivation of the resuscitation promoting factor B from Mycobacterium tuberculosis (319 visite)
J Biomol Struct Dyn (ISSN: 0739-1102, 1538-0254electronic, 0739-1102linking), 2013 Feb 1; 31(2): 195-205.
Impact Factor: 2.983
Dettagli Esporta in BibTeX Esporta in EndNote
Dolga AM, Letsche T, Gold M, Doti N, Bacher M, Chiamvimonvat N, Dodel R, Culmsee C
* Activation of KCNN3/SK3/K(Ca)2. 3 channels attenuates enhanced calcium influx and inflammatory cytokine production in activated microglia (441 visite)
Glia (ISSN: 1098-1136), 2012 Dec; 60(12): 2050-2064.
Impact Factor: 5.466
Dettagli Esporta in BibTeX Esporta in EndNote
Peluso R, Di Minno MND, Bruner V, Soscia E, Castiglione F, Manguso F, Iervolino S, Scarpa R
* Discovertebral Erosions in Patients with Enteropathic Spondyloarthritis (243 visite)
Journal Of Rheumatology (ISSN: 0315-162x), 2012 Dec; 39(12): 2332-2340.
Impact Factor: 3.258
Dettagli Esporta in BibTeX Esporta in EndNote
Kaprelyants AS, Mukamolova GV, Ruggiero A, Makarov VA, Demina GR, Shleeva MO, Potapov VD, Shramko PA
* Resuscitation-promoting Factors (Rpf): In Search of Inhibitors (331 visite)
Protein Pept Lett (ISSN: 0929-8665, 1875-5305), 2012 Oct; 19(10): 1026-1034.
Impact Factor: 1.994
Dettagli Esporta in BibTeX Esporta in EndNote
Ruggiero A, Tizzano B, Pedone E, Pedone C, Wilmanns M, Berisio R
* Crystal Structure of the Resuscitation-Promoting Factor (Delta DUF)RpfB from M. tuberculosis (333 visite)
J Mol Biol (ISSN: 0022-2836, 1089-8638, 1089-8638electronic), 2009 Jan 9; 385(1): 153-162.
Impact Factor: 3.871
Dettagli Esporta in BibTeX Esporta in EndNote
Selvaggi F, Cuocolo A, Giuliani A, Sciaudone G, Riegler G, Mainolfi C, Caprio MG, Panico M, Fiume I
* The role of scintigraphic defecography in the assessment of bowel function after restorative proctocolectomy for ulcerative colitis (242 visite)
International Journal Of Colorectal Disease (ISSN: 0179-1958, 0179-1958linking), 2006 Jul; 21(5): 448-452.
Impact Factor: 2.006
Dettagli Esporta in BibTeX Esporta in EndNote
Galdiero S, Vitiello M, Amodeo P, D'Isanto M, Cantisani M, Pedone C, Galdiero M
* Structural requirements for proinflammatory activity of porin P2 loop 7 from Haemophilus influenzae (427 visite)
Biochemistry (ISSN: 0006-2960, 1520-4995, 1520-4995electronic), 2006 Apr 11; 45(14): 4491-4501.
Impact Factor: 3.633
Dettagli Esporta in BibTeX Esporta in EndNote
Selavaggi F, Cuocolo A, Giuliani A, Sciaudone G, Riegler G, Mainolfi C, Caprio MG, Panico M, Fiume I
* The Role Of Scientigraphic Defecography In The Assessment Of Bowel Function After Restorative Proctocolectomy For Ulcerative Colitis (195 visite)
Int J Colorectal Dis, 2006; 5: 448-452.
Impact Factor: 2.017
Dettagli Esporta in BibTeX Esporta in EndNote
Fonti R, Latella G, Caprilli R, Frieri G, Marcheggiano A, Sambuy Y
Carbonic anhydrase I reduction in colonic mucosa of patients with active ulcerative colitis (224 visite)
Digestive Diseases And Sciences (ISSN: 0163-2116), 1998; 43(9): 2086-2092.
Impact Factor: 1.972
Dettagli Esporta in BibTeX Esporta in EndNote
20 Records (20 escludendo Abstract e Conferenze).
Impact factor totale: 75.828 (75.828 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 54.569 (54.569 escludendo Abstract e Conferenze).
Impact factor totale: 75.828 (75.828 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 54.569 (54.569 escludendo Abstract e Conferenze).
Last modified by Ultima modifica di Gennaro Angrisano on in data Thursday 14 January 2021, 17:58:39
19 views visite. Last view on Ultima visita in data Wednesday 17 February 2021, 18:16:16
ibb.cnr.it